Conditions: Essential Hypertension
Keywords: Essential Hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 328
Healthy volunteers: no

Brief summary:
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Detailed description:

Arms:
arm 1: Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks. arm 2: Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.

Interventions: intervention 1: Aliskiren intervention 2: Placebo to Aliskiren
Intervention descriptions: intervention 1: Aliskiren supplied in 150 mg and 300 mg tablets. intervention 2: Placebo to Aliskiren matching 150 and 300 mg tablets

Protocol document: